The Centers for Medicare & Medicaid Services (CMS) released the CY 2027 Medicare Advantage (MA) and Part D Final Rule and corresponding fact sheet on April 2, 2026.
Key takeaways
The CY 2027 Final Rule continues CMS’ recent push toward a more tightly managed Medicare Advantage environment. The rule places particular emphasis on benefit appropriateness, care continuity for high-need members, integration, and streamlined marketing and quality frameworks.
Across the rule, CMS generally advances policies that require plans and their partners to apply stronger operational discipline, while preserving flexibility where commenters raised concerns about unnecessary burden or disruption.
For Medicare Advantage organizations, providers, and intermediary partners, the clearest takeaway is that CMS is continuing to raise expectations around eligibility determination and consumer-facing operations while streamlining quality measurement. The rule continues CMS’ movement toward tighter oversight and simplification in areas that affect Special Needs Plans (SNPs), supplemental benefits, marketing, and Star Ratings.
Several themes stand out. CMS continues to prioritize aligned enrollment and continuity of care for dual-eligible individuals, while recognizing variation across state Medicaid managed care environments. CMS is also increasing oversight and transparency for supplemental benefits, especially Special Supplemental Benefits for the Chronically Ill (SSBCI), by requiring more objective and defensible eligibility processes.
At the same time, CMS is easing selected marketing and sales restrictions, signaling a willingness to reduce administrative friction where beneficiary protections can still be preserved through disclosure and consent-based safeguards. CMS is also continuing to refine the Star Ratings framework, including the further removal of process-oriented measures and continued use of the historical reward factor rather than the Health Equity Index reward for 2027.
For Part D, CMS is continuing to operationalize the Inflation Reduction Act-driven redesign. The Final Rule reinforces that plans must now move from initial implementation to ongoing execution under the new benefit structure.
For Part D sponsors and their partners, the central implication is operational. Plans will need to continue adapting bid, formulary, manufacturer engagement, and administrative processes to the redesigned benefit and related manufacturer obligations.
Dual Eligible Special Needs Plans (D-SNPs)
CMS finalized policies that reinforce aligned enrollment goals while preserving a limited pathway for certain Highly Integrated Dual Eligible (HIDE) SNPs and coordination-only D-SNPs to continue serving full-benefit dual-eligible individuals enrolled in Medicaid fee-for-service, subject to state-specific criteria.
CMS also replaced the “substantially similar” network requirement for passive enrollment crosswalks with continuity of care and care coordination capacity requirements and finalized a new off-cycle model of care submission process.
CMS is trying to balance integration goals with on-the-ground Medicaid variation. Plans operating in states with less comprehensive Medicaid managed care penetration may retain more flexibility than initially expected, but they will need to demonstrate operational readiness around care coordination, continuity of care, and model of care administration.
Supplemental benefits
CMS finalized several SSBCI policy changes that tighten eligibility, documentation, and administration requirements. Plans will need to use objective processes to demonstrate enrollee eligibility, make their SSBCI eligibility criteria publicly available, and comply with clarified rules for administering benefits through debit cards. At the same time, CMS removed an administrative requirement by rescinding the regulation requiring plans to notify enrollees mid-year about unused supplemental benefits.
Plans should expect greater scrutiny of how they define, document, and operationalize supplemental benefits, especially SSBCI. The practical implication is a need for more defensible clinical and operational processes.
Marketing
CMS finalized several changes that reduce administrative restrictions on beneficiary outreach and sales activity. These include eliminating the 12-hour waiting period between educational and marketing events at the same location, eliminating the 48-hour waiting period between scope of appointment completion and a personal marketing appointment, allowing scope of appointment forms to be collected at educational events, and revising Third-Party Marketing Organization disclaimer requirements.
CMS is moving away from rigid timing rules and toward a framework that relies more on disclosure, advance agreement, and beneficiary choice. Plans, field marketing organizations, and agents and brokers will have more flexibility in outreach and appointment-setting, but they will still need strong compliance controls around disclosures and event transitions.
Star Ratings
CMS finalized removal of 11 of the 12 measures proposed for elimination, retaining only the Diabetes Care – Eye Exam measure. CMS also finalized addition of the Depression Screening and Follow-Up measure beginning with the 2029 Star Ratings. Finally, CMS removed the Health Equity Index reward from the 2027 methodology and will instead continue the historical reward factor.
The direction of Star Ratings policy remains clear: fewer topped-out or less meaningful process measures and a more streamlined methodology. Plans should continue preparing for a more concentrated ratings environment in which fewer measures carry greater strategic weight.
Part D
CMS codified several Inflation Reduction Act-driven Part D changes, including the revised benefit structure, termination of the Coverage Gap Discount Program, and implementation of the Manufacturer Discount Program.
The strategic imperative for Part D is no longer initial implementation, but ongoing operationalization. Plans will need to continue adapting bid, formulary, manufacturer engagement, and administrative processes to the redesigned benefit and related manufacturer obligations.
Additional signals from CMS
In the proposed rule, CMS issued Requests for Information on C-SNP and I-SNP enrollment trends, risk adjustment, Quality Bonus Payments, well-being and nutrition, and regulatory burden. CMS did not respond to comments on these topics in the Final Rule, but the inclusion of these RFIs signals where the agency may focus future policy development.
Even where CMS did not finalize policy changes, it is continuing to build an agenda for future rulemaking. Plans and partners should treat these RFIs as an early signal of where additional policy and operational change may emerge in future years.
Bottom line
The CY 2027 Final Rule continues a broader pattern of CMS action: tighter oversight in areas tied to benefit appropriateness and operational accountability, paired with selective simplification where the agency believes burden can be reduced without weakening safeguards.
For plans and partners, the near-term priority is not just understanding what changed, but identifying where these finalized policies require stronger documentation, sharper operations, and more proactive planning for future CMS action.